1301 related articles for article (PubMed ID: 30386104)
1. Second-line rescue treatment of
Lin TF; Hsu PI
World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
[TBL] [Abstract][Full Text] [Related]
2. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
Hsu PI; Tsai FW; Kao SS; Hsu WH; Cheng JS; Peng NJ; Tsai KW; Hu HM; Wang YK; Chuah SK; Chen A; Wu DC
Am J Gastroenterol; 2017 Sep; 112(9):1374-1381. PubMed ID: 28719592
[TBL] [Abstract][Full Text] [Related]
3. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection.
Hsu PI; Tsay FW; Kao JY; Peng NJ; Chen YH; Tang SY; Kuo CH; Kao SS; Wang HM; Wu IT; Shie CB; Chuah SK; Wu DC;
Helicobacter; 2021 Oct; 26(5):e12840. PubMed ID: 34390083
[TBL] [Abstract][Full Text] [Related]
4. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
[TBL] [Abstract][Full Text] [Related]
5. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
[TBL] [Abstract][Full Text] [Related]
6. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC;
Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
[TBL] [Abstract][Full Text] [Related]
7. [Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of
Zhang M; Chen CY; Wang XT; Lyu B
Zhonghua Nei Ke Za Zhi; 2017 May; 56(5):368-374. PubMed ID: 28460509
[No Abstract] [Full Text] [Related]
8. Update on the second-line treatment of
Shih CA; Shie CB; Tai WC; Chuah SK; Lee HC; Hsu PI
Therap Adv Gastroenterol; 2023; 16():17562848231192750. PubMed ID: 37675247
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
10. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.
Pabón-Carrasco M; Keco-Huerga A; Castro-Fernández M; Saracino IM; Fiorini G; Vaira D; Pérez-Aísa Á; Tepes B; Jonaitis L; Voynovan I; Lucendo AJ; Lanas Á; Martínez-Domínguez SJ; Almajano EA; Rodrigo L; Vologzanina L; Brglez Jurecic N; Denkovski M; Bujanda L; Abdulkhakov RA; Huguet JM; Fernández-Salazar L; Alcaide N; Velayos B; Silkanovna Sarsenbaeva A; Zaytsev O; Ilchishina T; Barrio J; Bakulin I; Perona M; Alekseenko S; Romano M; Gravina AG; Núñez Ó; Gómez Rodríguez BJ; Ledro-Cano D; Pellicano R; Bogomolov P; Domínguez-Cajal M; Almela P; Gomez-Camarero J; Bordin DS; Gasbarrini A; Kupčinskas J; Cano-Català A; Moreira L; Nyssen OP; Mégraud F; O'Morain C; Gisbert JP;
United European Gastroenterol J; 2024 Feb; 12(1):122-138. PubMed ID: 38050339
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori.
Wu TS; Hsu PI; Kuo CH; Hu HM; Wu IC; Wang SSW; Chen YH; Wu DC; Su WW; Kuo FC
J Dig Dis; 2017 Sep; 18(9):537-542. PubMed ID: 28644575
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
[TBL] [Abstract][Full Text] [Related]
13. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
14. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG;
Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
[TBL] [Abstract][Full Text] [Related]
16. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg).
Nyssen OP; Vaira D; Pérez Aísa Á; Rodrigo L; Castro-Fernandez M; Jonaitis L; Tepes B; Vologzhanina L; Caldas M; Lanas A; Lucendo AJ; Bujanda L; Ortuño J; Barrio J; Huguet JM; Voynovan I; Lasala JP; Sarsenbaeva AS; Fernandez-Salazar L; Molina-Infante J; Jurecic NB; Areia M; Gasbarrini A; Kupčinskas J; Bordin D; Marcos-Pinto R; Lerang F; Leja M; Buzas GM; Niv Y; Rokkas T; Phull P; Smith S; Shvets O; Venerito M; Milivojevic V; Simsek I; Lamy V; Bytzer P; Boyanova L; Kunovský L; Beglinger C; Doulberis M; Marlicz W; Goldis A; Tonkić A; Capelle L; Puig I; Megraud F; Morain CO; Gisbert JP;
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2243-2257. PubMed ID: 34954341
[TBL] [Abstract][Full Text] [Related]
17. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.
Gisbert JP; Bermejo F; Castro-Fernández M; Pérez-Aisa A; Fernández-Bermejo M; Tomas A; Barrio J; Bory F; Almela P; Sánchez-Pobre P; Cosme A; Ortiz V; Niño P; Khorrami S; Benito LM; Carneros JA; Lamas E; Modolell I; Franco A; Ortuño J; Rodrigo L; García-Durán F; O'Callaghan E; Ponce J; Valer MP; Calvet X;
Am J Gastroenterol; 2008 Jan; 103(1):71-6. PubMed ID: 17764498
[TBL] [Abstract][Full Text] [Related]
18. Novel and Effective Therapeutic Regimens for
Hu Y; Zhu Y; Lu NH
Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
[No Abstract] [Full Text] [Related]
19. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for
Zhang YW; Hu WL; Cai Y; Zheng WF; Du Q; Kim JJ; Kao JY; Dai N; Si JM
World J Gastroenterol; 2018 Oct; 24(40):4596-4605. PubMed ID: 30386109
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of second-line regimens for
Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
